Using a candidate gene approach, we analyzed the methylation status of the promoter-associated CpG islands of 11 wellcharacterized tumor suppressor genes by methylation-specific polymerase chain reaction in five multiple myeloma (MM) cell lines and 56 patients with malignant plasma cell disorders. The frequency of aberrant methylation among the patient samples was 46.4% for SOCS-1, 35.7% for p16, 21.4% for E-cadherin, 12.5% for DAP kinase and p73, 1.8% for p15, MGMT as well as RARb, and 0% for TIMP-3, RASSF1A and hMLH1. We found at least one hypermethylated gene in 80.4% of the primary patient samples, while 33.9% harbored two or more hypermethylated genes. For the first time, we show that p73 may be hypermethylated in MM and thus be involved in the pathogenesis of plasma cell disorders. Hypermethylation of p16 at diagnosis was associated with a poorer prognosis. In patients with plasma cell leukemia, we found frequent simultaneous hypermethylation of p16, E-cadherin and DAP kinase. We conclude that aberrant methylation of tumor suppressor genes is a common event in malignant plasma cell disorders and that there is a correlation between methylation patterns and clinical characteristics in MM patients.
Introduction
Multiple myeloma (MM) is a B-cell neoplasm that is characterized by the accumulation of malignant plasma cells in the bone marrow. Previous molecular studies have largely focused on acquired genetic aberrations in MM. Important changes in DNA sequence include chromosomal translocations involving the immunoglobulin heavy chain locus on chromosome 14q32 and various partner genes such as cyclin D1, cyclin D3, fibroblast growth factor receptor 3 and c-maf, as well as mutations of Nras and K-ras. [1] [2] [3] The accumulation of genetic events is thought to be crucial for the malignant transformation of plasma cells. 1 There is increasing evidence that in addition to genetic aberrations epigenetic processes play a major role in carcinogenesis. Aberrant methylation of gene promoter regions is the most widely studied epigenetic abnormality in human malignancies and is associated with loss of gene function. This epigenetic event acts as an alternative to mutations and deletions to disrupt tumor suppressor gene function. 4, 5 It was reported previously that hypermethylation of the cell cycle inhibitors p15 and p16, [6] [7] [8] [9] the apoptosis regulator DAP kinase 10 and the tumor suppressor RASSF1A 11 may occur in MM patients. Additionally, we have recently identified hypermethylation-associated silencing of the suppressor of cytokine signaling-1 (SOCS-1) gene to be a frequent epigenetic aberration in MM. 12 It could be demonstrated that there are specific methylation patterns in various types of human malignancies. 13 Unlike genetic alterations in cancer, epigenetic changes are potentially reversible. Demethylating agents such as 5-aza-2 0 -deoxycytidine are capable of reactivating tumor suppressor genes that are silenced by promoter hypermethylation. 4, 14 Characterization of the methylation profile of candidate tumor suppressor genes that have been established to play a role in tumorigenesis may provide significant insight into the molecular pathogenesis of MM. Furthermore, methylation patterns may be predictive for clinical behavior and response to therapy. 15, 16 To gain further insight into specific pathways that are relevant in the multistep transformation process of normal plasma cells to MM, we have therefore applied methylation analysis of 11 candidate genes to five MM cell lines and 56 samples from patients with plasma cell disorders as well as 20 nonmalignant bone marrow samples. The list of tumor suppressor genes includes the cell cycle regulators p15, p16 and p73, the tissue inhibitor of matrix metalloproteinases-3 (TIMP-3), E-cadherin, the DNA repair genes O 6 -methylguanine DNA methyltransferase (MGMT) and hMLH1, DAP kinase, RASSF1A, the retinoic acid receptor b (RARb) and the cytokine regulator SOCS-1. It could be shown that each of these genes may be affected by aberrant CpG island methylation in association with transcriptional silencing in various types of human malignancies. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Material and methods
Human tissue samples
Bone marrow (BM) and peripheral blood (PB) specimens were obtained during routine clinical assessment of 53 MM patients and three patients with monoclonal gammopathy of undetermined significance (MGUS), who presented at the University Hospital Aachen, Germany, between 1995 and 2002. MM diagnosis and staging classification were made in accordance with standard criteria. 28 The main clinical characteristics of the patient cohort are summarized in Table 1 . Control BM samples were aspirated from 20 patients with nonmetastatic solid tumors or malignant lymphoma without BM infiltration or hematopoietic dysfunction as part of the routine staging procedures. Informed consent was obtained from all patients following institutional guidelines. Normal PB samples were collected from healthy volunteers. Mononuclear cells from BM and PB were separated by density gradient centrifugation prior to further analysis.
Cell lines
We obtained the MM cell lines U266, OPM-2, RPMI8226 and LP-1 from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). XG1 cells were kindly provided by PC Heinrich (RWTH Aachen, Germany).
Methylation-specific polymerase chain reaction (MSP)
MSP 29 was used for qualitative analysis of the methylation status of the 11 tumor suppressor genes. After bisulfite treatment of genomic DNA, which converts all unmethylated cytosines to uracils, the subsequent PCR amplification is performed in two separate reactions with two different primer pairs that are specific for either the methylated or the unmethylated sequence. Primers for MSP analysis are designed to discriminate between methylated and unmethylated alleles after bisulfite treatment and to anneal only to DNA that has been bisulfite-converted. A purification of plasma cells prior to further analysis was not performed because of the high sensitivity of the MSP technique with a detection limit of approximately 0.1% of methylated DNA present in an otherwise unmethylated sample. 29 Genomic DNA was isolated from cell lines and primary tissues using standard methods. Approximately 1 mg of DNA was sodium bisulfite-modified and subjected to MSP as described previously. 29 A detailed list of MSP primers that specifically recognize either unmethylated (U) or methylated (M) gene sequences is given in Table 2 . Reactions were hot-started at 951C for 5 min and held at 801C before addition of 0.625 U of Taq polymerase (Sigma, St Louis, MO, USA). Temperature conditions for PCR for all genes except TIMP-3 were as follows: 35 cycles of 951C for 30 s, 601C for 30 s and 721C for 30 s, followed by one cycle of 721C for 5 min. For TIMP-3 analysis, conditions were 35 cycles of 951C for 30 s, 591C for 30 s and 721C for 30 s, followed by one cycle of 721C for 5 min. PCR products were separated on 2.5% agarose gels and visualized by ethidium bromide staining.
Statistical methods
Overall survival curves were plotted according to the method of Kaplan and Meier, and compared using the log-rank test. Survival was calculated from the date of diagnosis until the patients' death or last visit. Correlation between variables was estimated using the Fisher's exact two-sided test. All calculations were performed using the SAS statistical software (version 8.02, SAS Institute, Cary, NC, USA).
Results
We determined the methylation status of 11 tumor suppressor genes in five MM cell lines, 56 patients with neoplastic plasma cell disorders and 20 nonmalignant BM specimens. Figure 2 . In MM cell lines, multiple epigenetic changes could be demonstrated. Aberrant methylation of up to eight of the 11 genes per cell line was observed. All genes except p15 and hMLH1 were hypermethylated in at least one MM cell line.
We then analyzed 56 samples from patients with plasma cell disorders. The frequency of aberrant methylation among the patient samples was 46.4% (26/56) for SOCS-1, 35.7% (20/56) for p16, 21.4% (12/56) for E-cadherin, 12.5% (7/56) for DAP kinase and p73, 1.8% (1/56) for p15, MGMT as well as RARb, and 0% (0/56) for TIMP-3, RASSF1A and hMLH1. At least one hypermethylated gene was found in 80.4% (45/56) of the primary patient samples, while 33.9% (19/56) harbored two or more aberrantly methylated genes. Among the 11 candidate genes analyzed, SOCS-1 was most often affected by hypermethylation in our patient cohort. In patients with plasma cell leukemia (PCL), there was frequent simultaneous hypermethylation of p16, E-cadherin and DAP kinase. For the first time, we demonstrate that p73 may be hypermethylated in MM. MSP for p15 was additionally performed using alternative primer pairs for MSP analysis, 29 yielding identical results in all patient samples and cell lines. In contrast to the results from patients with MM and MGUS, no methylation of any of the 11 tumor suppressor genes was found in 20 nonmalignant BM samples.
We have then explored possible correlations between methylation data and clinical parameters of the 56 patients. Factors analyzed included age, gender, white blood cell count (WBC), hemoglobin levels (Hb), platelet counts (PLT), creatinine, serum calcium levels, serum lactate dehydrogenase (LDH), paraprotein isotype, disease stage and presence of lytic bone lesions. Hypermethylation of p16 (Po0.01, two-sided Fisher's exact), DAP kinase (P ¼ 0.01, two-sided Fisher's exact) and Ecadherin (Po0.01, two-sided Fisher's exact) was associated with PCL. Among PCL samples, there was a higher incidence of two or more hypermethylated gene loci (Po0.05, two-sided Fisher's exact).
Aberrant methylation of p16 was associated with lower Hb levels (P ¼ 0.04, two-sided Fisher's exact), higher LDH levels (P ¼ 0.02, two-sided Fisher's exact) and higher creatinine (P ¼ 0.02, two-sided Fisher's exact). Furthermore, hypermethylation of E-cadherin and DAP kinase was associated with a lower platelet count (P ¼ 0.01 and 0.03, respectively; two-sided Fisher's exact). There were no correlations between the methylation status of the other eight genes and any of the clinical parameters analyzed.
For survival analysis only those 36 patients, from whom material was obtained at diagnosis, were included. We found that in these patients, hypermethylation of p16 was correlated with a poorer survival (P ¼ 0.03, log-rank test; Figure 3 ), while the methylation status of any of the other 10 genes had no prognostic impact.
Discussion
The aim of this study was to determine the methylation patterns of patients with malignant plasma cell disorders and explore possible correlations between aberrant methylation and clinical parameters. To our knowledge, this study is the first to analyze the methylation status of multiple promoter-associated CpG islands from a cohort of patients with MM and MGUS. Our data provide evidence that a variety of genes regulating different pathways may be affected by aberrant methylation in MM.
We found a higher methylation frequency in MM cell lines compared to the patient samples. There was aberrant methylation of up to eight of the 11 tumor suppressor genes analyzed, and all genes except p15 and hMLH1 were hypermethylated in at least one MM cell line. These findings are in accordance with data obtained from solid tumors, 30 indicating that cancer cell lines tend to exhibit higher levels of CpG island hypermethylation than the primary malignancies they represent.
The majority of the 56 patients (80.4%) exhibited hypermethylation of at least one of the 11 candidate genes. The genes most frequently affected by aberrant methylation were SOCS-1, p16, E-cadherin, DAP kinase and p73. Hypermethylation of MGMT, p15 and RARb were rare events, while there was no methylation of TIMP-3, hMHL1 and RASSF1A. These methylation patterns in malignant plasma cell disorders differ from previously reported data in other hematopoietic malignancies. In acute leukemias, aberrant methylation of p15, E-cadherin, SOCS-1, DAP kinase and p73 13, [31] [32] [33] are the most common events, while in non-Hodgkin's lymphomas DAP kinase, p16, MGMT, RARb and p73 13, 34 are predominantly affected by CpG island hypermethylation.
We found a significantly higher methylation frequency of p16, DAP kinase and E-cadherin as well as a higher total number of hypermethylated genes in PCL. These data from the PCL samples indicate that the accumulation of epigenetic events affecting genes regulating cell cycle control, cell adhesion and apoptosis may in addition to genetic aberrations contribute to a more aggressive phenotype in MM or reflect a molecular progression from MM with few silenced genes. PCL is a distinct clinical MM subgroup that appears to have a characteristic methylation profile.
The role of p16 in MM pathogenesis has been discussed controversially. Previous reports have already shown that hypermethylation of p16 is a common phenomenon in MM and MGUS. [6] [7] [8] [9] 35 While two studies found a correlation of aberrant p16 methylation with a poorer outcome, 8, 9 Guillerm 
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O Galm et al et al 36 could not demonstrate a negative prognostic impact of p16 methylation. In our patient cohort, hypermethylation of p16 was associated with a shortened survival, thus providing further evidence for the role of methylation markers as a prognostic factor.
In agreement with Depil et al, 37 we found that SOCS-1 hypermethylation appears to have no impact on MM prognosis, and there was no correlation of the SOCS-1 methylation status with clinical parameters. We discovered aberrant methylation of p73 to be a novel epigenetic event in MM. Hypermethylation of p73 has been previously implicated in the pathogenesis of acute leukemias and malignant lymphomas. 38, 39 Our results regarding the methylation status of p15 are in contrast to previously published data. 6, 35 Using two different primer pairs for MSP analysis, we found p15 to be hypermethylated in only one MM patient and in none of the five MM cell lines analyzed. Given the fact that cell lines tend to carry a higher number of hypermethylated genes in comparison to their corresponding primary tumors, 30 we draw the conclusion that the role of p15 hypermethylation in MM may have been overestimated. Hypermethylation of p15 appears to be restricted mostly to acute leukemias. 13 In summary, this study demonstrates that aberrant gene promoter methylation is a common phenomenon in malignant plasma cell disorders. In addition to the accumulation of genetic aberrations, this epigenetic phenomenon may further contribute to the phenotype of MM cells. In order to explore possible links between genetic and epigenetic events in the multistep transformation process of plasma cells, future studies are needed to examine a broad spectrum of methylation changes as well as genetic alterations in different stages of MM at diagnosis and during follow-up.
Our data provide further evidence that methylation patterns may be useful as prognostic indicators at MM diagnosis. However, the number of cases studied limits the clinical implications of our results. To better define and assess the clinical impact of methylation markers in MM, it is therefore necessary to establish a detailed methylation profile in a larger number of patient samples, where multivariable analysis will be possible. This knowledge may help to develop new markers for detection of minimal residual disease and determine candidate patients for epigenetically targeted salvage therapy regimens.
The demethylating drugs 5-aza-2 0 -deoxycytidine and 5-azacytidine have recently been shown to be effective in patients with acute leukemia, myelodysplastic syndrome and chronic myelogenous leukemia. [40] [41] [42] [43] The increasing evidence for the important role of epigenetic aberrations in malignant plasma cell disorders may serve as a basis for the use of demethylating therapeutic approaches in MM in the future. Overall survival (Kaplan-Meier curve) in 36 MM patients with or without aberrant methylation of p16 at diagnosis.
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